NeuraLight

The importance of eye movements in neurodegenerative diseases has been known for decades. Authors of this review in Nature from the University of Otago state that "Different saccadic paradigms precisely reflect cognitive and motor characteristics, and may be useful biomarkers of disease severity and progression". https://t.ly/7eo2K

May 15th is the international Huntington's Disease (HD) Awareness Day. HD is characterized by a loss of control of motor function that causes also abnormal eye movements at early stages. This article provides insights on the patterns and progression of eye movement abnormalities throughout the stages of #HD. https://t.ly/05aaP

NeuraLight is going to present at Biomed Israel 2024 in Tel Aviv. We'd love to meet! Email us at partnerships@neuralight.ai

During the last decades, new approaches to eye movements and vision were developed, with new insights and technological development. This nice review from Rutgers University provides an interesting historical perspective. https://t.ly/CTk7u

In this recent review, researchers from Icahn School of Medicine at Mount Sinai and Cleveland Clinic discuss the disease spectrum of Multiple Sclerosis #MS. The authors point out that "There is a need for more sensitive assessments to unmask clinical manifestations". https://t.ly/SmDpM

A growing body of literature has investigated changes in #eye movements as a result of #Alzheimer's disease (AD). This recent review paper from Huazhong University of Science and Technology and NYU Tandon School of Engineering describes the past and recent attempts of researchers to detect the different relationships between eye movement and AD. The authors conclude that "The development of methods that can accurately denoise and classify and quickly process massive eye movement data is quite significant for detecting eye movements in early diagnosis of AD". https://t.ly/hNd1N

In only 2 weeks, NeuraLight will attend the #ALS Drug Development Summit! Email partnerships@neuralight.ai and schedule a meeting in Boston with our team! https://t.ly/mfP4l

In this video from Cure Parkinson's, Prof. Olivier Rascol, a world-renowned expert in #movementdisorders and an member of NeuraLight advisory board, explains the recent exciting findings from the #LixiPark trial, indicating that #lixisenatide, a #Diabetes drug similar to #Ozempic, may be able to delay the progression of motor symptoms in #Parkinson’s disease. https://t.ly/xTHbx

One of the key potential advantages of using #eyemovements in clinical practice is the ability to differentiate #CNS diseases with similar symptoms at early stages. Researchers from Kyorin University, Fukushima Medical University and The University of Tokyo found out that saccades can provide useful information for differentiating between #Parkinson's Disease and Multiple System Atrophy (#MSA) at early stages, suggesting a link with specific brain pathology. https://t.ly/_9QuZ

A new paper from in Frontiers in Aging Neuroscience, describes the different types of eye movement abnormalities in a variety of neurological disorders that lead to cognitive impairment https://t.ly/YX12g